Radiological Sciences and Radiopharmaceuticals


The roadmap of the Radiological Sciences and Radiopharmaceuticals activities can be summarized in the key-phrase:
from bench to bed-side

Major Objectives / Activities


Resources - critical mass assembly

Participating Laboratories / Groups

Major accomplishments in this thematic area can be found in the latest Scientific Report of INRASTES.



  • Peptide-based radiopharmaceuticals: Radiolabeled somatostatin, bombesin, neurotensin, gastrin and other peptide-based analogs have been and will continue to be developed and screened as candidates for receptor-targeted diagnostic tumor imaging using SPECT and PET, as well as for peptide receptor targeted therapy (PRTT).
  • Selected analogs are undergoing Phase I clinical trials in European clinical centers (Austria, UK, Germany, Italy and The Netherlands).
  • Neuroprotective peptides (humanin, colivelin), alpha-thymosins (inflammation imaging) and anti-microbial peptides (infection imaging) labeled with Tc-99m via different chelating systems.
  • Bioinorganic compounds: New mixed ligand chelating systems for technetium, rhenium and other metals in different oxidation states.
  • Radiolabeled small bioactive molecules: Pharmacophore- (quinazolines for EGFR imaging, cationic compounds for targeting of energized mitochondria, quinolones for discrimination of infection from aseptic inflammation) coupled (radio)metal chelates, mainly 99mTc-based.
  • Antibodies: Monoclonal Antibodies labeled with gamma-, beta- and positron-emitting radioisotopes (Technetium-99m, Rhenium-186/188, Lutetium-177, Samarium-153, Arsenic-74, Niobium-90) for targeted imaging and therapy of cancer.
  • Nanoparticles: Multimodal (SPECT/PET/Optical) mannosylated dextrans for sentinel lymph node detection; Gd-based nanoparticle structures (iron-oxide/gold) labeled with Gallium-68, as dual-modality imaging agents.

Back to Radiological Sciences and Radiopharmaceuticals main page.

Radiobiology, Biodosimetry and Radioprotection

  • Development and validation of biomarkers using high throughput methodologies for assessing absorbed doses and health risk in case of radiation exposure emergencies, radiological accidents or terrorists acts.
  • Development of a cytokinesis–block micronucleus (CBMN) assay for measuring DNA damage, cytostasis and cytotoxicity induced by cytotoxic agents (ionizing radiation, drugs). Evaluation of induced radiosensitivity by various drugs.
  • Mechanistic insights on the aetiology of low-and high-LET radiation-induced chromosomal aberrations and risk for carcinogenesis using conventional and interphase cytogenetics.
  • Induction and repair kinetics of radiation-induced chromatid breaks during G2/M transition as a biological basis for predicting enhanced radiosensitivity and susceptibility to carcinogenesis at individual level.

Back to Radiological Sciences and Radiopharmaceuticals main page.

Radioecology / Environmental Radioactivity

  • Development of a user-friendly, ready-to-use by stakeholders, commercial organism-kit for environmental quality assessment purposes.
  • Providing an innovative tool for the remote control of the radioactive releases in the marine environment from local and / or regional / global radiological events.
  • To advance the ERICA Tool by introducing further biological parameters for more accurate estimations of dose to non-human organisms.
  • Size distribution of air-borne radionuclides / aerosol technology

Link to research group
Back to Radiological Sciences and Radiopharmaceuticals main page.

Radioactive waste management

  • Contribute essentially towards the formulation of the national strategy for integrated solutions regarding radioactive waste management.
  • Establish the national laboratory for conditioning and long-term storage of radioactive waste until removal for disposal at the respective national disposal facilities.
  • Develop further activities and infrastructure concerning the radiological characterization and decommissioning of relevant facilities / devices.

Back to Radiological Sciences and Radiopharmaceuticals main page.

Resources - critical mass assembly

  • Experience and infrastructure (in terms of expert staff and advanced facilities) developed over the last decade(s) as a result of European and National projects.
  • Currently running projects on receptor - targeted radiopharmaceuticals (EMC_BioSynthema Collaboration Agreement) and newly (within 2013) approved for funding projects (TranScan, ARISTEIA II) on translational research, therapeutic radioligands in oncology.
  • Intense service provision to public and private entities in the fields of Radiopharmaceuticals QC and radioisotope/radiopharmaceutical distribution throughout Greece.
  • Provision of services related to Radiation Protection of man and environment to a variety of authorities and stakeholders (issuing of certificates).
  • Support by GAEC and the government to equip and sustain a National Point for radioactive waste management.

Back to Radiological Sciences and Radiopharmaceuticals main page.